Tirzepatide

Tirzepatide (LY3298176) is a synthetic 39-amino acid peptide engineered as a dual agonist at the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). It is acylated at lysine-20 with a C20 fatty diacid chain via a linker, enabling reversible albumin binding that extends its plasma half-life to approximately five days and permits once-weekly subcutaneous dosing.

Receptor engagement is imbalanced: tirzepatide binds the GIPR with affinity equal to native GIP but engages GLP-1R with roughly five-fold lower affinity than native GLP-1, showing approximately 20-fold lower potency in cAMP assays at GLP-1R. At clinically efficacious doses, predicted receptor occupancy is consequently higher at GIPR than at GLP-1R.

At GLP-1R, tirzepatide additionally shows biased agonism, favoring cAMP signaling over beta-arrestin recruitment (below 10% Emax at beta-arrestin1) and driving substantially less receptor internalization than native GLP-1. Because beta-arrestin1 suppresses insulin secretion in response to GLP-1 stimulation, reduced arrestin engagement likely amplifies tirzepatide's net insulinotropic effect relative to its degree of GLP-1R occupancy.

Dual incretin receptor activation produces several coordinated metabolic effects: • Glucose-dependent stimulation of pancreatic beta-cell insulin secretion • Suppression of glucagon secretion from alpha cells • Appetite reduction and decreased caloric intake via hypothalamic GLP-1R and GIPR pathways • Slowing of gastric emptying, attenuating postprandial glucose excursions • Improvement of peripheral insulin sensitivity, partly mediated through GIPR expression in adipose tissue

Tirzepatide has been studied in two large Eli Lilly-sponsored phase 3 programs. The SURPASS program (SURPASS-1 through SURPASS-5, approximately 7,000 participants total) evaluated glycemic outcomes in adults with type 2 diabetes. Across all five trials, tirzepatide at 5, 10, and 15 mg reduced HbA1c by a mean of 1.87% to 2.59%, superior to semaglutide 1 mg (SURPASS-2), titrated insulin degludec (SURPASS-3), and insulin glargine (SURPASS-4, SURPASS-5). In SURPASS-3 (n=1,437, 52 weeks), tirzepatide 15 mg reduced HbA1c by 2.37% versus 1.34% with insulin degludec, while decreasing body weight by 12.9 kg compared with a 2.3 kg gain in the insulin group. Tirzepatide (Mounjaro) received FDA approval for type 2 diabetes on May 13, 2022.

The SURMOUNT program assessed tirzepatide for weight management in adults without diabetes. SURMOUNT-1 (NCT04184622, n=2,539, 72 weeks; Jastreboff et al., NEJM 2022) showed mean body weight reductions of 16.0%, 21.4%, and 22.5% at 5, 10, and 15 mg respectively versus 2.4% with placebo; 39.7% of participants on 15 mg lost at least 25% of body weight, and fat mass fell approximately 33.9% versus 10.9% for lean mass. A pooled meta-analysis of SURMOUNT-1, -3, and -4 (n=3,901; Liu et al., Int J Clin Pharm 2024) found average weight loss of 18.7%, with 56.1% achieving at least 20% and 38.7% at least 25% loss; BMI fell 7.65 kg/m2 and waist circumference decreased 14 cm. SURMOUNT-4 reported 25.8% mean weight loss over 88 weeks at maximum tolerated dose.

In the head-to-head SURMOUNT-5 trial (NCT05822830, n=751, 72 weeks; Jastreboff et al., NEJM May 2025), tirzepatide 15 mg produced 20.2% weight loss versus 13.7% with semaglutide 2.4 mg, and 31.6% versus 16.1% achieved at least 25% weight reduction. Tirzepatide (Zepbound) received FDA approval for chronic weight management on November 8, 2023, and for moderate-to-severe obstructive sleep apnea in adults with obesity on December 20, 2024, following the SURMOUNT-OSA trials.

Typical dosage: 2.5-15 mg (weekly).

Dosing information derives from FDA prescribing information for Mounjaro (type 2 diabetes) and Zepbound (obesity, obstructive sleep apnea). Both products use an identical subcutaneous injection schedule administered once weekly on the same day each week. Injection sites are the abdomen, thigh, or upper arm, rotated with each dose.

Titration schedule (minimum 4 weeks at each dose before advancing): • Weeks 1-4: 2.5 mg once weekly (initiation only; not an approved maintenance dose) • Weeks 5-8: 5 mg once weekly • Weeks 9-12: 7.5 mg once weekly • Weeks 13-16: 10 mg once weekly • Weeks 17-20: 12.5 mg once weekly • Week 21 onward: 15 mg once weekly (maximum approved dose)

Dose escalation may be delayed if gastrointestinal tolerability warrants. Missed doses: administer within 96 hours of the scheduled day; if more than 96 hours have elapsed, skip the dose and resume the regular schedule. In clinical trials, many participants reached maintenance at 10 mg or 15 mg depending on individual tolerability. Concurrent use with other GLP-1 receptor agonists or tirzepatide-containing products is not recommended per FDA labeling.

This information reflects published FDA labeling and registered clinical trial protocols and is provided for educational and reference purposes only. It does not constitute medical advice. Appropriate dosing for any individual requires evaluation by a licensed healthcare provider.

Lyophilized (before reconstitution)

Refrigerate 2–8°C before first use. Do not freeze. Protect from light in the original carton.

Reconstituted

Mounjaro and Zepbound: after first use, the pen or vial may be kept at room temperature (≤30°C) for up to 21 days. Do not refreeze; discard after the in-use period.

For general storage chemistry (bacteriostatic vs sterile water, freeze-thaw, BUD framework), see Storage & handling.

Last reviewed: July 1, 2026

The SURPASS program formally evaluated tirzepatide across multiple combination regimens in type 2 diabetes, providing registered clinical trial evidence for the following:

• Metformin: used as background therapy in most SURPASS trials; tirzepatide produced consistent HbA1c and weight reductions regardless of co-administration. • SGLT2 inhibitors: optional background in SURPASS-3; no significant difference in HbA1c outcomes was observed in the metformin-plus-SGLT2i subgroup versus metformin alone. • Sulfonylureas: background in SURPASS-2 and -4; hypoglycemia risk increases to approximately 10-14% in this combination versus under 2% on tirzepatide without an insulin secretagogue. • Basal insulin (degludec or glargine): studied in SURPASS-3, -4, and -5; adding tirzepatide to existing insulin glargine allowed insulin dose reductions of 3.8 to 4.4 units while improving glycemic control; hypoglycemia monitoring is required.

In the obesity setting, no randomized trial evidence supports combining tirzepatide with other approved anti-obesity pharmacotherapies (naltrexone/bupropion, phentermine/topiramate, orlistat). Any such combinations represent off-label, anecdotal use. Combination with research peptides (e.g., growth hormone secretagogues, BPC-157) has no clinical trial evidence and is entirely anecdotal. Concurrent use with another GLP-1 receptor agonist is not recommended per FDA labeling.

Tirzepatide is approved by the U.S. Food and Drug Administration for one or more clinical indications. Refer to the prescribing information for full safety and dosing details.

PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.

Reported side effects: Similar to semaglutide: GI disturbances, nausea, potential pancreatitis

Tirzepatide carries an FDA boxed warning for thyroid C-cell tumors, based on rodent carcinogenicity studies; its relevance to humans has not been determined. It is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2), and in those with known severe hypersensitivity to tirzepatide or its excipients.

Gastrointestinal effects are the most common adverse events, typically emerging during dose escalation and diminishing with continued use. Pooled phase 3 data show odds ratios relative to placebo of 4.26 for nausea, 8.35 for vomiting, and 3.57 for diarrhea (Liu et al., 2024). In SURPASS-3, nausea occurred in 12-24% and diarrhea in 15-17% of tirzepatide participants. Additional adverse events reported in at least 5% of patients in registration trials include decreased appetite, constipation, dyspepsia, and abdominal pain. Treatment discontinuation attributable to adverse events occurred at approximately 3.27 times the rate of placebo.

Additional safety considerations: • Pancreatitis: acute pancreatitis, including fatal and nonfatal hemorrhagic forms, has been reported in clinical trials; persistent severe abdominal pain warrants prompt evaluation. • Gallbladder disease: cholelithiasis and cholecystitis have been observed in treated patients. • Hypoglycemia: low risk when tirzepatide is used without insulin secretagogues or insulin; risk rises to 10-14% with sulfonylureas and is meaningfully elevated with concurrent insulin. • Sinus tachycardia: documented mean heart rate increases of several beats per minute. • Acute kidney injury: may occur secondary to dehydration from severe gastrointestinal events. • Injection-site reactions: local erythema, pruritus, and discomfort are reported.

Tirzepatide is not approved for type 1 diabetes. Use during pregnancy and lactation is not recommended. Long-term dedicated cardiovascular outcome data from the SURPASS-CVOT trial were pending as of mid-2026.